Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: The JMAAV study

Modern Rheumatology

Volumn 22, Issue 3, 2012, Pages 394-404

  Ozaki, Shoichi ^a   Atsumi, Tatsuya ^b   Hayashi, Taichi ^c   Ishizu, Akihiro ^b   Kobayashi, Shigeto ^d   Kumagai, Shunichi ^e   Kurihara, Yasuyuki ^a   Kurokawa, Manae S ^f   Makino, Hirofumi ^g   Nagafuchi, Hiroko ^a   Nakabayashi, Kimimasa ^h   Nishimoto, Norihiro ⁱ   Suka, Machi ^j   Tomino, Yasuhiko ^d   Yamada, Hidehiro ^a   Yamagata, Kunihiro ^c   Yoshida, Masaharu ^k   Yumura, Wako ^l  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

^d JUNTENDO UNIVERSITY   (Japan)

^e KOBE UNIVERSITY   (Japan)

^f ST MARIANNA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g OKAYAMA UNIVERSITY   (Japan)

^h KYORIN UNIVERSITY   (Japan)

ⁱ WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^j JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k TOKYO MEDICAL UNIVERSITY   (Japan)

^l JICHI MEDICAL UNIVERSITY   (Japan)

more..

Author keywords

Anti neutrophil cytoplasmic antibody; Microscopic polyangiitis; Prophylaxis; Pulmonary limited vasculitis; Severity based treatment

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; PREDNISOLONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; JAPANESE; KIDNEY FAILURE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELOPEROXIDASE ANTI NEUTROPHIL CYTOPLASMIC ANTIBODIES ASSOCIATED VASCULITIS; PLASMAPHERESIS; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION; SHORT FORM 36; TREATMENT OUTCOME; VASCULITIS;

AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ASIAN CONTINENTAL ANCESTRY GROUP; CYCLOPHOSPHAMIDE; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JAPAN; MALE; MIDDLE AGED; PEROXIDASE; PREDNISOLONE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84865392910     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-011-0525-5     Document Type: Article

References (20)

1. Jennette JC, Falk RJ. Clinical and pathological classification of ANCA-associated vasculitis: What are the controversies? Clin Exp Immunol. 1995;101(Suppl 1):18-22.
2. van der Woude FJ, Rasmussen N, Lobatto S, Wiik A, Permin H, van Es LA, et al. Autoantibodies against neutrophils and monocytes: Tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet. 1985;1(8426):425-9. (Pubitemid 15173133)
3. Falk RJ, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med. 1988;318(25):1651-7.
4. Suzuki Y, Takeda Y, Sato D, Kanaguchi Y, Tanaka Y, Kobayashi S, et al. Clinicoepidemiological manifestations of RPGN and ANCA-associated vasculitides: An 11-year retrospective hospitalbased study in Japan. Mod Rheumatol. 2009;20(1):54-62.
5. Falk RJ, Gross WL, Guillevin L, Hoffman G, Jayne DR, Jennette JC, et al. Granulomatosis with polyangiitis (Wegener's): An alternative name for Wegener's granulomatosis. Ann Rheum Dis. 2011;70(4):704.
6. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: An analysis of 158 patients. Ann Intern Med. 1992;116(6):488-98.
7. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349(1):36-44. (Pubitemid 36765101)
8. De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52(8):2461-9. (Pubitemid 41117433)
9. Ozaki S. ANCA-associated vasculitis: Diagnostic and therapeutic strategy. Allergol Int. 2007;56(2):87-96. (Pubitemid 46984236)
10. Koyama A, Yamagata K, Makino H, Arimura Y, Wada T, Nitta K, et al. A nationwide survey of rapidly progressive glomerulonephritis in Japan: Etiology, prognosis and treatment diversity. Clin Exp Nephrol. 2009;13(6):633-50.
11. Flossmann O, Bacon P, de Groot K, Jayne D, Rasmussen N, Seo P, et al. Development of comprehensive disease assessment in systemic vasculitis. Ann Rheum Dis. 2007;66(3):283-92. (Pubitemid 46579626)
12. Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum. 1997;40(2): 371-80. (Pubitemid 27114101)
13. Fukuhara S, Suzukamo Y. Manual of SF-36v2 Japanese version. Kyoto: Institute for Health Outcomes and Process Evaluation Research; 2004.
14. Guillevin L, Lhote F, Gayraud M, Cohen P, Jarrousse B, Lortholary O, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine. 1996;75(1):17-28. (Pubitemid 26041085)
15. Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Le Toumelin P. The Five-Factor Score revisited: Assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine. 2011;90(1):19-27.
16. Weidner S, Geuss S, Hafezi-Rachti S, Wonka A, Rupprecht HD. ANCA-associated vasculitis with renal involvement: An outcome analysis. Nephrol Dial Transpl. 2004;19(6):1403-11. (Pubitemid 38786731)
17. Lapraik C, Watts R, Bacon P, Carruthers D, Chakravarty K, D'Cruz D, et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford). 2007;46(10):1615-6.
18. Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68(3):310-7.
19. Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, Ducroix JP, et al. Azathioprine or methotrexate maintenance for ANCAassociated vasculitis. N Engl J Med. 2008;359(26):2790-803.
20. Hiemstra TF, Walsh M, Mahr A, Savage CO, de Groot K, Harper L, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized controlled trial. JAMA. 2010;304(21): 2381-8.